（同仁堂公告） 近日，同仁堂（600085）发布公告称，公司分支机构同仁堂制药厂收到加拿大卫生部核准签发的《产品 许可证（三类）》，儿感清口服液、锁阳固精丸、人参健脾丸、大黄虫丸获得加拿大产品注册。 公告同样指出，这些产品若在加拿大销售，还需完成包括生产场地的加拿大生产质量体系认证等行政审 批事项，该等审批可能存在一定不确定性。本次获批事宜对公司近期经营业绩不会产生重大影响。 ...

政策动向 国家药监局药审中心发布《罕见病用化学药物药学研究指导原则（试行）》 2月24日，中国药审官微发布消息显示，为落实《国务院办公厅关于全面深化药品医疗器械监管改革促 进医药产业高质量发展的意见》（国办发〔2024〕53号），加大对罕见病药物研发的支持力度，进一步 完善罕见病药物技术指导原则体系，鼓励和加速推动罕见病药物研发上市，在国家药品监督管理局的部 署下，药审中心组织制定了《罕见病用化学药物药学研究指导原则（试行）》，自发布之日起施行。 药械审批 恒瑞医药：1类创新药SHR-1918注射液获受理并纳入优先审评程序 2月24日，恒瑞医药(600276.SH)公告称，公司子公司北京盛迪医药有限公司收到国家药监局下发的《受 理通知书》，公司1类创新药SHR-1918注射液的药品上市许可申请获受理，且已被纳入优先审评程序。 该药品用于治疗成人和12岁及以上的未成年人纯合子家族性高胆固醇血症（HoFH）患者。SHR-1918注 射液是公司自主研发的血管生成素样蛋白3（ANGPTL3）单克隆抗体，通过抑制ANGPTL3的活性，从 而降低血清中的甘油三酯（TG）和LDL-C水平。截至目前，相关项目累计研发投入约2 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 今日聚焦 1、东阳光：筹划收购东数一号控制权 股票停牌 东阳光2月24日公告，公司正在筹划通过发行股份的方式收购宜昌东数一号投资有限责任公司控制权， 并募集配套资金。本次交易预计构成《上市公司重大资产重组管理办法》规定的重大资产重组且构成关 联交易，本次交易不会导致公司实际控制人发生变更。因本次交易尚存在不确定性，公司股票已于2026 年2月24日开市起停牌，并将于2026年2月25日开市起继续停牌，预计停牌(累计)时间不超过10个交易 日。 2、同德化工：收到《执行通知书》及《执行裁定书》 被冻结、扣划银行存款人民币5392.59万元 同德化工2月24日公告，公司及全资子公司收到《执行通知书》及《执行裁定书》，冻结、扣划被执行 人同德科创材料有限公司、山西同德爆破工程有限责任公司、山西同德化工(002360)股份有限公司的银 行存款人民币5392.59万元。 6、光线传媒：电影《飞驰人生3》累计票房收入约29.26亿元 光线传媒2月24日公告，公司子公司参与的影片《飞驰人生3》累计票房收入(含服务费)约29.26亿元，超 过公司最近一个会计年度经审计的合并财 ...

同仁堂制药厂产品儿感清口服液、锁阳固精丸、人参健脾丸、大黄䗪虫丸取得加拿大卫生部颁发的《产 品许可证(三类)》系产品上市许可。上述产品若拟在加拿大销售，后续还需根据加拿大卫生部法规要 求，完成包括但不限于对生产场地的加拿大生产质量体系认证等行政审批事项，该等审批可能存在一定 不确定性。本次获批事宜对公司近期经营业绩不会产生重大影响。 智通财经APP讯，同仁堂(600085.SH)发布公告，公司分支机构北京同仁堂股份有限公司同仁堂制药厂 (以下简称同仁堂制药厂)收到加拿大卫生部核准签发的《产品许可证(三类)》，同仁堂制药厂产品儿感 清口服液、锁阳固精丸、人参健脾丸、大黄䗪虫丸获得加拿大产品注册。 ...

同仁堂制药厂产品儿感清口服液、锁阳固精丸、人参健脾丸、大黄虫丸取得加拿大卫生部颁发的《产品 许可证(三类)》系产品上市许可。上述产品若拟在加拿大销售，后续还需根据加拿大卫生部法规要求， 完成包括但不限于对生产场地的加拿大生产质量体系认证等行政审批事项，该等审批可能存在一定不确 定性。本次获批事宜对公司近期经营业绩不会产生重大影响。 同仁堂（600085）(600085.SH)发布公告，公司分支机构北京同仁堂股份有限公司同仁堂制药厂(以下简 称同仁堂制药厂)收到加拿大卫生部核准签发的《产品许可证(三类)》，同仁堂制药厂产品儿感清口服 液、锁阳固精丸、人参健脾丸、大黄虫丸获得加拿大产品注册。 ...

每经AI快讯，2月24日，同仁堂（600085）(600085.SH)公告称，公司分支机构同仁堂制药厂收到加拿大 卫生部核准签发的《产品许可证(三类)》，儿感清口服液、锁阳固精丸、人参健脾丸、大黄虫丸获得加 拿大产品注册。但这些产品若在加拿大销售，还需完成包括生产场地的加拿大生产质量体系认证等行政 审批事项，该等审批可能存在一定不确定性。本次获批事宜对公司近期经营业绩不会产生重大影响。 ...

Core Viewpoint - The traditional Chinese medicine (TCM) industry is experiencing structural opportunities amid policy promotion, price adjustments, technological innovations, and differentiated demand, with mixed performance among leading companies in the sector [1] Revenue and Profit Analysis - Yunnan Baiyao achieved both revenue and net profit growth, reporting revenue of 21.257 billion yuan, up 3.92%, and a net profit of 3.633 billion yuan, up 13.93%, marking a historical high for the period [2][6] - In contrast, Pizhou Huang experienced declines in both revenue and net profit, with revenue of 5.379 billion yuan, down 4.81%, and a net profit of 1.442 billion yuan, down 16.22%, marking its first revenue decline since its listing in 2003 [2][6] - Other companies like Huayuan Sanjiu, Tongrentang, and Baiyunshan reported revenue growth without corresponding profit increases, with Baiyunshan's revenue at 41.835 billion yuan, up 1.93%, but net profit down 1.31% to 2.516 billion yuan [2][8] Industry Trends - The TCM industry is transitioning from resource dependence to quality orientation, with enhanced quality control of medicinal materials [3] - The industry is undergoing deep price adjustments, with supply chains facing both pressure and restructuring, leading to a differentiated pricing landscape for medicinal materials [3] Innovation and R&D Focus - Innovation is emphasized as a core driver for growth in the pharmaceutical industry, with major TCM companies focusing on various aspects of research and development [10] - Yunnan Baiyao is actively pursuing projects in innovative drug development and has over 160 ongoing projects, including several innovative drugs in clinical trials [10][11] - Huayuan Sanjiu has increased its R&D investment by 68.99% to 662 million yuan, with a total of 205 projects in progress, following its acquisition of a 28% stake in Tian Shili [11] Future Outlook - The ability of these companies to convert their strategic innovations and R&D efforts into performance growth remains to be seen, with expectations for future developments in the TCM sector [12]

Core Viewpoint - The traditional Chinese medicine (TCM) industry is experiencing structural opportunities driven by policy support, price adjustments, technological innovations, and differentiated demand in the first half of 2025, with notable performance disparities among leading companies [1][3]. Group 1: Company Performance - Yunnan Baiyao achieved revenue of 212.57 billion yuan, a year-on-year increase of 3.92%, and a net profit of 36.33 billion yuan, up 13.93%, marking a historical high for the period [2][4]. - Baiyun Mountain reported revenue growth of 1.93% to 418.35 billion yuan, but net profit fell by 1.31% to 25.16 billion yuan [5][6]. - Huaren Sanjiu's revenue increased by 4.99% to 148.10 billion yuan, while net profit dropped significantly by 24.31% to 18.15 billion yuan [6][10]. - Tongrentang's revenue was 97.69 billion yuan, a slight increase of 0.06%, but net profit decreased by 7.39% to 9.45 billion yuan [5][6]. - Pianzaihuang experienced a revenue decline of 4.81% to 53.79 billion yuan and a net profit drop of 16.22% to 14.42 billion yuan, marking its first revenue decline since its listing in 2003 [4][5]. Group 2: Industry Trends - The TCM industry is transitioning from resource dependence to quality orientation, with enhanced quality control of medicinal materials [3][4]. - The industry is undergoing deep price adjustments, with supply chain pressures and restructuring, leading to a differentiated pricing landscape [3][4]. - The normalization of centralized procurement is accelerating market differentiation within the industry [3]. Group 3: Research and Innovation - Companies are emphasizing innovation as a core driver for growth, with Baiyun Mountain focusing on innovative drugs, generic drug consistency evaluation, and product redevelopment [7][10]. - Pianzaihuang is advancing multiple new drug projects, including 18 research projects and several clinical studies [8]. - Huaren Sanjiu has increased its R&D investment by 68.99% to 6.62 billion yuan, with 205 projects in progress following its acquisition of a 28% stake in Tian Shili [10][11]. - Yunnan Baiyao is integrating AI technologies across its operations, aiming for a digital transformation that enhances efficiency [9].